Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Rhea-AI Summary
Palisade Bio (NASDAQ:PALI) has released a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). The segment focuses on the company's lead candidate PALI-2108 and its potential impact on FSCD treatment.
Dr. Feagan, a Professor of Medicine at Western University and Senior Scientific Director at Alimentiv, Inc., discussed the significant unmet need in FSCD treatment and highlighted PALI-2108's novel approach. The drug candidate is designed to provide localized treatment that reduces side effects while maintaining anti-inflammatory and anti-fibrotic activity.
Positive
- Novel localized treatment approach potentially reducing side effects
- Lead candidate addresses both inflammation and fibrotic process in FSCD
- Endorsement from leading KOL in IBD research
Negative
- Early-stage development with no efficacy data presented
- No timeline provided for clinical development
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
– Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, MD, FRCPC. Dr. Feagan is a Professor of Medicine, Epidemiology & Biostatistics at Western University, a practicing gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc. He is a founding member of the Stenosis Therapy and Antifibrotic Research (STAR) Consortium, the founder of Robarts Clinical Trials (now Alimentiv), and globally recognized leaders in IBD clinical research. Dr. Feagan has directed more than 140 randomized controlled trials in Crohn’s disease and ulcerative colitis, developed widely used outcome measures including the Robarts Histopathology Index, and published extensively in the field. He is internationally recognized as a leading authority in FSCD and clinical trial design.
As part of the segment, Dr. Feagan discussed FSCD and the challenges with current approved therapies, highlighting the significant unmet need for more effective therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on the novel approach of PALI-2108 and how it could potentially impact the overall treatment landscape. PALI-2108’s localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.
The Virtual Investor KOL Connect segment featuring Palisade Bio is now available here.
For more information about PALI-2108 and the Company’s development plans, visit www.palisadebio.com.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What is PALI-2108 and how does it treat Fibrostenotic Crohn's Disease?
Who is Dr. Brian Feagan and why is his opinion on PALI-2108 significant?
What are the current challenges in treating Fibrostenotic Crohn's Disease?
Where can investors access Palisade Bio's KOL presentation about PALI-2108?
